Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 1.00 |
| ▸ | CA2 | P00918 | 5/20 | 1.00 |
| ▸ | CA9 | Q16790 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.88 |
| ▸ | MPO | P05164 | 9/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11594154 | 1.00 | CA12 (1.00) | CA12CA2CA9TSHRKDM4E | |
| SCHEMBL11594819 | 1.00 | CA12 (1.00) | CA12CA2CA9TSHRKDM4E | |
| SCHEMBL26087471 | 0.94 | CA12 (0.92) | CA12CA2CA9TSHRKDM4E | |
| SCHEMBL11241212 | 0.94 | CA12 (1.00) | CA12CA2CA9TSHRKDM4E | |
| SCHEMBL3857624 | 0.91 | CA12 (0.83) | CA12CA2CA9TSHRKDM4E | |
| SCHEMBL11122843 | 0.91 | CA12 (0.83) | CA12CA2CA9TSHRKDM4E | |
| SCHEMBL11118157 | 0.91 | CA12 (0.83) | CA12CA2CA9TSHRKDM4E | |
| SCHEMBL8017532 | 0.91 | CA12 (0.83) | CA12CA2CA9TSHRKDM4E | |
| SCHEMBL5935029 | 0.91 | CA12 (0.83) | CA12CA2CA9TSHRKDM4E | |
| SCHEMBL11118835 | 0.91 | CA12 (0.83) | CA12CA2CA9TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153712-A1 | PROCESS FOR PRODUCING A POLYBENZOXAZINE MONOMER | UNIVERSITÉ DE MONTPELLIER (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153712-A1 | PROCESS FOR PRODUCING A POLYBENZOXAZINE MONOMER | WIZ, PCBP1, RNF168 | CA12 1605/4885CA2 3001/4885CA9 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.